Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment.

CONCLUSIONS: In HFrEF patients with CKD, RAS inhibitors are associated with reduction in mortality in stage 3B CKD, but the association is less clear in stage 4 or 5 CKD.
PMID: 30737061 [PubMed - as supplied by publisher]

Source: European Journal of Internal Medicine - February 5, 2019 Category: Internal Medicine Authors: Higuchi S, Kohsaka S, Shiraishi Y, Katsuki T, Nagatomo Y, Mizuno A, Sujino Y, Kohno T, Goda A, Yoshikawa T, West Tokyo Heart Failure (WET-HF) Registry Investigators Tags: Eur J Intern Med Source Type: research